3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
4
Non Small Cell Lung Cancer Metastatic
3
Neoplasms
2
Recurrence
1
Neoplasm Metastasis
1
Neoadjuvant Non-Small Cell Lung Cancer
1
Lymphoma, Large-Cell, Anaplastic
1
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
1
Advanced Non-Small Cell Lung Cancer
1
ALK Positive Non-small Cell Lung Cancer
1
Interventions
Cyclophosphamide
33
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
15
Rituximab
14
Tacrolimus
13
Busulfan
12
Vincristine
11
Prednisone
11
Methotrexate
11
Filgrastim
11
Doxorubicin
11
Cyclosporine
11
Radiotherapy
10
Brentuximab Vedotin
10
Antilymphocyte Serum
10
Methylprednisolone
8
Cytarabine
8
Melphalan
7
Cisplatin
6
Ifosfamide
5
Gemcitabine
5
merphos
4
ibritumomab tiuxetan
4
Sirolimus
4
Flow Cytometry
4
Dexamethasone
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Large-Cell, Anaplastic
×
lorlatinib
×
Clear all
NCT03505554
2023-08-07
CRU3
University of Milano Bicocca
Phase 2
Unknown
12 enrolled